AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Akebia Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $227.33M | $152.18M | $170.30M | $176.95M | $140.29M | $128.20M | $111.12M | $6.82M | – | – | 96.2% | +49.4% |
| Auryxia | $181.54M | $152.18M | $170.30M | – | – | – | – | – | – | – | 76.9% | +19.3% |
| Vafseo | $45.79M | $0 | $0 | – | – | – | – | – | – | – | 19.4% | – |
| License, collaboration and other revenue | $8.86M | $8.00M | $24.32M | $115.54M | $71.36M | $166.41M | $223.88M | $200.92M | $181.23M | $1.54M | 3.8% | +10.8% |
By region
From the segment and revenue-disaggregation notes of Akebia Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.